• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Meikle Phillip Terry Ii

    10/18/24 8:25:32 PM ET
    $BBLG
    Industrial Specialties
    Health Care
    Get the next $BBLG alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Meikle Phillip Terry II

    (Last) (First) (Middle)
    C/O BONE BIOLOGICS CORP
    BURLINGTON WOODS DR. SUITE 100

    (Street)
    BURLINGTON MA 01803

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/16/2024
    3. Issuer Name and Ticker or Trading Symbol
    Bone Biologics Corp [ BBLG ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Phillip Meikle 10/18/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BBLG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBLG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BBLG
    SEC Filings

    View All

    Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bone Biologics Corp (0001419554) (Filer)

    9/4/25 7:05:25 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form EFFECT filed by Bone Biologics Corp

    EFFECT - Bone Biologics Corp (0001419554) (Filer)

    9/3/25 12:15:04 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form S-3/A filed by Bone Biologics Corp

    S-3/A - Bone Biologics Corp (0001419554) (Filer)

    8/29/25 10:29:48 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM). NELL-1 has several unique prope

    9/4/25 7:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. The Company is underta

    9/3/25 7:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Announces Closing of $5.0 Million Public Offering

    Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants have an exercise price of $4.00 per share, are exercisable immediately upon issu

    6/30/25 4:10:00 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Meikle Phillip Terry Ii

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:30 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Angle Siddhesh Rajendra

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:24 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Stroever Bruce

    4 - Bone Biologics Corp (0001419554) (Issuer)

    6/6/25 5:01:18 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Leadership Updates

    Live Leadership Updates

    View All

    Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

    Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

    10/21/24 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

    Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

    1/11/24 8:00:00 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    $BBLG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/14/24 7:19:34 PM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    11/13/24 11:14:34 AM ET
    $BBLG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

    SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

    6/28/24 4:15:43 PM ET
    $BBLG
    Industrial Specialties
    Health Care